AbbVie submits new drug application for vitiligo, revenue surpasses $60 billion in 2025

K-LinePoet · 2026-02-12T15:11:40+00:00

AbbVie submitted an application to the FDA and EMA for Upadacitinib to treat vitiligo in 2026. If approved, it will be the world's first systemic drug. In 2025, revenue was $61.16 billion, with immunology business growing by 14%. Recently, the stock price has been stable, and several institutions have updated their ratings, focusing on future pipelines and profit potential.

K-LinePoet

2026-02-12 15:11:40

Abstract generation in progress

Healthcare Observation Network, February 9, 2026: AbbVie announced that it has submitted a new indication application to the U.S. FDA and the European EMA for Upadacitinib for the treatment of adult and adolescent non-segmental vitiligo. If approved, this will become the world’s first systemic drug for vitiligo. On February 6, the company released its full-year 2025 results, with revenue reaching $61.16 billion, an 8.6% increase year-over-year, officially entering the $60 billion club. Among them, global sales of Upadacitinib totaled $8.304 billion, up 39.1%, and Skyrizi sales reached $17.562 billion, up 49.9%.

Recent Stock Performance

Over the past 7 days (February 5 to February 12, 2026), AbbVie’s stock price fluctuated within a range of 2.80%, with a high of $225.82 (February 6) and a low of $214.04 (February 5). The latest closing price on February 12 was $223.19, up 1.04% for the day, with trading volume significantly increasing to 8.07 million shares on February 11. During the same period, the pharmaceutical sector rose by 0.83%, and the Dow Jones Industrial Average increased by 0.50%.

Financial Report Analysis

AbbVie’s full-year 2025 financial report shows that immunology business revenue reached $30.4 billion, a 14% increase, becoming the core growth driver. The neuroscience segment has been upgraded to a core pillar, with Vraylar generating $3.621 billion in revenue, and Botox earning $3.769 billion in the migraine field. The company acquired the Capstan tLNP platform to advance its CAR-T therapy pipeline.

Institutional Views

On February 5, 2026, several Wall Street institutions updated their ratings: TD Cowen maintained a buy rating with a target price of $280; Evercore lowered its target price to $228; UBS maintained a hold rating with a target price of $230. Analysts are focused on the company’s pipeline progress and the potential for upward revisions of earnings guidance.

The above content is compiled from public information and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.